Dec 21, 2020
AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer
Nov 25, 2020
AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19
Nov 13, 2020
AIM ImmunoTech Provides Third Quarter 2020 Business Update
Nov 02, 2020
AIM ImmunoTech Announces PLOS ONE's Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen's Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Oct 30, 2020
BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year
Oct 22, 2020
AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th
Oct 06, 2020
AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 'Long Haulers' in the AMP-511 ME/CFS Clinical Trial of Ampligen
Sep 22, 2020
AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands
Sep 16, 2020
AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19
Sep 10, 2020
AIM ImmunoTech to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14th
 11   12   13   14   15     16    17   18   19   20   21 
 <<   <   >   >>